GT Biopharma Reports Third Quarter 2024 Financial Results
14 nov. 2024 16h00 HE
|
GT Biopharma, Inc.
GTB-3650 TriKE® Phase 1 trial first patient dosed expected in Q4 2024; initial clinical data expected in Q2 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in...
GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024
24 sept. 2024 09h15 HE
|
GT Biopharma, Inc.
SAN FRANCISCO, CALIFORNIA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...
GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
15 mai 2024 17h00 HE
|
GT Biopharma, Inc.
IND clearance for GTB-3650, a 2nd generation nanobody TriKE® for treatment of CD33+ leukemia expected in Q2 2024Phase 1 trial initiation with GTB-3650 expected in 2H 2024Anticipate IND submission for...
MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
22 févr. 2024 10h30 HE
|
MAIA Biotechnology, Inc.
Topline data expected in second half of 2024THIO-101 will be the first completed clinical study of a telomere targeting agent in the field of cancer drug discovery and treatment CHICAGO, IL, Feb. ...
Invectys Announces Initiation of Phase 1/2a Clinical Trial in Solid Tumors and Change in Leadership
13 juil. 2023 09h08 HE
|
Invectys, Inc.
Houston, TX, USA, July 13, 2023 (GLOBE NEWSWIRE) -- Invectys, Inc., a clinical-stage immuno-oncology company developing novel therapies for the treatment of advanced cancers, today announces it has...
GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
15 mai 2023 17h00 HE
|
GT Biopharma, Inc.
Cash of approximately $19.9 million as of March 31, 2023, provides ample runway to fund operations into Q2 2024; anticipated to be sufficient to achieve IND clearance for GTB-3650 and GTB-5550, and...
GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
30 mars 2023 17h00 HE
|
GT Biopharma, Inc.
Proforma cash of approximately $23.0 million includes $16.5 million in cash as of December 31, 2022, plus $6.5 million in gross proceeds received from a registered direct offering priced at a premium...
GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
24 févr. 2023 09h00 HE
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the...
GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities
02 févr. 2023 09h46 HE
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...
GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market
30 déc. 2022 08h00 HE
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Dec. 30, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...